Clearbridge Investments LLC Boosts Stock Position in Insmed Incorporated (NASDAQ:INSM)

Clearbridge Investments LLC lifted its stake in Insmed Incorporated (NASDAQ:INSM) by 3.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,878,450 shares of the biopharmaceutical company’s stock after purchasing an additional 69,683 shares during the period. Clearbridge Investments LLC’s holdings in Insmed were worth $129,688,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC boosted its stake in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC lifted its holdings in shares of Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 248 shares in the last quarter. Spire Wealth Management bought a new position in shares of Insmed in the fourth quarter valued at approximately $47,000. Smartleaf Asset Management LLC grew its stake in Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in Insmed during the 4th quarter worth approximately $86,000.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. UBS Group raised their price target on shares of Insmed from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Guggenheim reissued a “buy” rating and set a $101.00 price objective on shares of Insmed in a research note on Tuesday, February 25th. Bank of America upped their target price on Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a research note on Thursday, March 20th. Stifel Nicolaus lowered their price target on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Finally, HC Wainwright reissued a “buy” rating and set a $90.00 price objective on shares of Insmed in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $94.00.

Insmed Stock Up 0.4 %

INSM opened at $77.99 on Monday. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The business’s 50-day moving average price is $78.18 and its 200-day moving average price is $74.00. The company has a market cap of $14.12 billion, a P/E ratio of -13.95 and a beta of 1.28.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. On average, equities analysts expect that Insmed Incorporated will post -4.56 EPS for the current year.

Insiders Place Their Bets

In other news, insider Martina M.D. Flammer sold 3,344 shares of Insmed stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total value of $220,403.04. Following the sale, the insider now directly owns 102,766 shares in the company, valued at approximately $6,773,307.06. This trade represents a 3.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $77.03, for a total value of $1,444,312.50. Following the transaction, the chief executive officer now owns 334,186 shares of the company’s stock, valued at approximately $25,742,347.58. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock valued at $42,992,528 in the last quarter. Insiders own 4.60% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.